尼莫地平联合泛癸利酮治疗缺血性脑卒中的临床疗效  

Clinical Efficacy of Nimodipine Combined with Ubidecarenone in the Treatment of Ischemic Stroke

作　　者：单丽妮[1] 闫新玲[2] 李真[2] 李丙选[2] 

机构地区：[1]潍坊市益都中心医院药剂科,山东潍坊262500 [2]潍坊市益都中心医院神经内科,山东潍坊262500

出　　处：《医学综述》2016年第9期1870-1872,共3页Medical Recapitulate

摘　　要：目的探讨尼莫地平联合泛癸利酮治疗缺血性脑卒中的临床疗效。方法将2010年3月至2013年3月潍坊市益都中心医院收治的157例缺血性脑卒中患者依据随机数字表法分为观察组(79例)和对照组(78例)。观察组给予尼莫地平40 mg,口服,每日3次;泛癸利酮20 mg,口服,每日3次,2周为1个疗程。对照组单用尼莫地平40 mg,口服,每日3次。比较两组患者的临床疗效、治疗前后简易智力状态量表(MMSE)、汉密尔顿抑郁量表(HAMD)、巴塞尔指数(Balthel)评分及不良反应情况。结果观察组总有效率高于对照组[93.7%(74/79)比79.5%(62/78)],差异有统计学意义(P<0.05)。治疗后,观察组HAMD低于对照组[(5.6±1.7)分比(10.3±2.9)分],MMSE、Balthel评分高于对照组[(23±3)分比(20±3)分,(96±13)分比(71±12)分],差异有统计学意义(P<0.01)。观察组患者不良反应发生率为8.9%(7/79),对照组为11.5%(9/78),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论尼莫地平联合泛癸利酮治疗缺血性脑卒可提高临床疗效,是一种安全而有效的药物,值得临床推广应用。Objective To study the clinical efficacy of nimodipine combined with ubidecarenone treat- ment of ischemic stroke. Methods Total of 157 ischemic stroke patients admitted to Weifang Yidu Central Hospital from Mar. 2010 to Mar. 2013 were divided into observation group（79 cases） and control group （78 cases ） according to random number table method. The observation group was given nimodipine 40 mg, orally, three times a day;ubidecarenone 20 mg, oral, 3 times per day,2 weeks as a treatment course. The control group was given nimodipine 40 mg, oral ,3 times a day. The clinical efficacy, Mini Mental State Examination （MMSE） , Hamilton depression rating scale（ HAMD）, Baltherl index（Balthel） score and adverse reactions of the two groups were compared. Results The total effective rate of the observation group was higher than the control group [ 93.7% （ 74/79 ） vs 93.7% （ 62/78 ） ], the difference was statistically significant （ P 〈 0.05 ）. After treatment, HAMD of the observation group was lower than the control group [ （ 5.6 ± 1.7 ） scores vs （ 10.3 ± 2.9 ） scores ], MMSE, Balthel of the observation group were higher than the control group [ （23 ±3） scores vs （20 ±3） scores,（96 ±13） scores vs （71 ± 12） scores] ,the differences were statisti- cally significant （P 〈 0. 01 ）. The incidence of adverse reactions of the observation group was 8.9% （7/79）, of the control group was 11.5% （9/78）, the difference had no statistical significance （P 〉 0.05 ）. Conclusion Nimodipine combined with ubidecarenonetreatment of ischemic stroke can improve the clinical efficacy, and is safe and effective, thus is worthy of popularization and application,

关 键 词：缺血性脑卒中 尼莫地平 泛癸利酮 神经评分 疗效 

分 类 号：R543[医药卫生—心血管疾病] R962[医药卫生—内科学]